In the last trading session, 1.83 million shares of the Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) were traded, and its beta was 1.84. Most recently the company’s share price was $3.47, and it changed around -$0.48 or -12.15% from the last close, which brings the market valuation of the company to $217.24M. ZNTL currently trades at a discount to its 52-week high of $18.07, offering almost -420.75% off that amount. The share price’s 52-week low was $2.66, which indicates that the current value has risen by an impressive 23.34% since then. We note from Zentalis Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.6 million shares, with the 3-month average coming to 2.00 million.

Zentalis Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 1.89. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 6 recommended ZNTL as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Zentalis Pharmaceuticals Inc is expected to report earnings per share of -0.8 for the current quarter.

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information

Instantly ZNTL has showed a red trend with a performance of -12.15% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.44 on recent trading dayincreased the stock’s daily price by 21.85%. The company’s shares are currently down -77.10% year-to-date, but still down -12.37% over the last five days. On the other hand, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is 15.67% up in the 30-day period. We can see from the shorts that 7.05 million shares have been sold at a short interest cover period of 5.49 day(s).

The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 65.3% from its current value. Analyst projections state that ZNTL is forecast to be at a low of $4 and a high of $55.

Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts

Zentalis Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -71.25 percent over the past six months and at a 38.26% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 3.90% in revenue this quarter, and will report a decrease of -671.43% in the next quarter.

Forecasts for the next quarter put sales growth at -100.00%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -50.05%.

ZNTL Dividends

Zentalis Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in December.

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 3.47% of Zentalis Pharmaceuticals Inc shares, and 98.18% of them are in the hands of institutional investors. The stock currently has a share float of 101.71%. Zentalis Pharmaceuticals Inc stock is held by 192.0 institutions, with MATRIX CAPITAL MANAGEMENT COMPANY, LP being the largest institutional investor. By 2024-06-30, it held 19.6902% of the shares, which is about 13.96 million shares worth $57.1 million.

FMR LLC, with 12.2383% or 8.68 million shares worth $35.49 million as of 2024-06-30, holds the second largest percentage of outstanding shares.